Stockreport

ArriVent BioPharma Reports Full Year 2024 Financial Results [Yahoo! Finance]

ArriVent BioPharma, Inc.  (AVBP) 
PDF Global pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollment Selected next-gen [Read more]